GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Liabilities-to-Assets

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Liabilities-to-Assets : 0.38 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. China Resourcesnjiu Medical & Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥15,521 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥41,248 Mil. Therefore, China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.38.


China Resourcesnjiu Medical & Pharmaceutical Co Liabilities-to-Assets Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Liabilities-to-Assets Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.37 0.36 0.35 0.40

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.41 0.39 0.40 0.38

Competitive Comparison of China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets falls into.



China Resourcesnjiu Medical & Pharmaceutical Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=15886.582/40148.456
=0.40

China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=15521.319/41247.674
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


China Resourcesnjiu Medical & Pharmaceutical Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.
Executives
Yang Zhan Ao Executives
Independent director
Li De Ming Supervisors
Lin Xi Ping Supervisors
Fang Ming Director
Mai Yi Executives

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines